基本信息
views: 0
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
I trained as a medicinal chemist at the University of Salerno (Italy) where I gained my degree (BSc and MSc in Medicinal Chemistry and Pharmaceutical Technology, part of the Pharmacy Degree) with a final year project on development of epigenetic inhibitors for the prostate cancer treatment. The interest in the fascinating field of drug discovery and epigenetics brought me to the United Kingdom in 2015 when I enrolled in a drug discovery PhD project in parasitology. I completed the PhD studies in October 2019 with a thesis titled “Identification of new compounds targeting the Schistosoma mansoni protein methylation machinery”.
I have been working as a Research Associate in the drug discovery field, focusing on the early-stage compound identification, target validation, medicinal chemistry optimisation and pre-clinical drug development with in vivo studies on Schistosomiasis animal model. I always enjoy working in interdisciplinary environments and bridging the biological underpinnings of the specific research topic and the chemical investigation for drug discovery applications.
Research Interests
Papers共 18 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
bioRxiv : the preprint server for biology (2024)
Journal of medicinal chemistryno. 23 (2023): 15801-15822
Pharmaceuticsno. 5 (2023)
Wellcome open research (2023): 146-146
Pharmaceuticsno. 7 (2023): 1869-1869
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Load More
Author Statistics
#Papers: 20
#Citation: 136
H-Index: 5
G-Index: 11
Sociability: 5
Diversity: 2
Activity: 22
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn